Search research articles
Contact Us
Filters
Showing results (21-30 of 65) with videos related to
Page
of 7
Sort By:
Orvosi Hetilap
|
January 14, 1996
[Correlation between p-53 expression and clinical resistance in testicular cancer]
E Hanna, I Bodrogi, E Institoris, et al.
Orvosi Hetilap
|
October 30, 1983
[Evaluation of serum alpha-1-fetoprotein studies in patients with testicular tumors receiving adjuvant and curative chemotherapy]
I Tóth, I Bodrogi, M Baki, et al.
Neoplasma
|
January 1, 1983
Inclusion of cisplatinum (cis-DDP, Platidiam, Lachema) into combined chemotherapeutic protocol for the treatment of testicular cancer
I Bodrogi, M Baki, I Hindy, et al.
Orvosi Hetilap
|
January 19, 1997
[Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer]
H Eid, E Institoris, I Bodrogi, et al.
Orvosi Hetilap
|
April 11, 1976
[Gamma glutamyl transpeptidase determination in malignant neoplastic diseases]
J Kralovánszky, I Bodrogi, G Tarján, et al.
Medical and Pediatric Oncology
|
January 1, 1994
A study of children, fathered by men treated for testicular cancer, conceived before, during, and after chemotherapy
M Babosa, M Baki, I Bodrogi, et al.
Anticancer Research
|
November 1, 1996
Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression
H Eid, I Bodrogi, B Csókay, et al.
Oncology
|
January 1, 1980
Forms and results of mitolactol therapy
I Hindy, J Szántó, I Bodrogi, et al.
Journal of Cancer Research and Clinical Oncology
|
March 14, 1998
Do metallothioneins affect the response to treatment in testis cancers?
H Eid, L Géczi, I Bodrogi, et al.
Orvosi Hetilap
|
September 18, 1999
[The clinical value of mdm-2 (proto-oncogene) expression in testicular cancer, Correlation with tumor progression]
M Bak, L Géczi, E Institioris, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 65) with videos related to
Sort By:
Page
of 7
Orvosi Hetilap
|
January 14, 1996
[Correlation between p-53 expression and clinical resistance in testicular cancer]
E Hanna, I Bodrogi, E Institoris, et al.
Orvosi Hetilap
|
October 30, 1983
[Evaluation of serum alpha-1-fetoprotein studies in patients with testicular tumors receiving adjuvant and curative chemotherapy]
I Tóth, I Bodrogi, M Baki, et al.
Neoplasma
|
January 1, 1983
Inclusion of cisplatinum (cis-DDP, Platidiam, Lachema) into combined chemotherapeutic protocol for the treatment of testicular cancer
I Bodrogi, M Baki, I Hindy, et al.
Orvosi Hetilap
|
January 19, 1997
[Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer]
H Eid, E Institoris, I Bodrogi, et al.
Orvosi Hetilap
|
April 11, 1976
[Gamma glutamyl transpeptidase determination in malignant neoplastic diseases]
J Kralovánszky, I Bodrogi, G Tarján, et al.
Medical and Pediatric Oncology
|
January 1, 1994
A study of children, fathered by men treated for testicular cancer, conceived before, during, and after chemotherapy
M Babosa, M Baki, I Bodrogi, et al.
Anticancer Research
|
November 1, 1996
Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression
H Eid, I Bodrogi, B Csókay, et al.
Oncology
|
January 1, 1980
Forms and results of mitolactol therapy
I Hindy, J Szántó, I Bodrogi, et al.
Journal of Cancer Research and Clinical Oncology
|
March 14, 1998
Do metallothioneins affect the response to treatment in testis cancers?
H Eid, L Géczi, I Bodrogi, et al.
Orvosi Hetilap
|
September 18, 1999
[The clinical value of mdm-2 (proto-oncogene) expression in testicular cancer, Correlation with tumor progression]
M Bak, L Géczi, E Institioris, et al.
Page
of 7